Deals Between Pharma and Academia Thriving

The Financial Times reports that pharmaceutical companies, including Astra Zeneca, Pfizer and GlaxoSmithKline have struck large deals with universities this year. The incentives to pharma include new sources of possible new megabuster pharmaceuticals while universities benefit from the infusion of cash, particularly in light of NIH grants that have decreased when adjusted for inflation. These partnerships differ from the traditional ones, where universities have pursued the research; on the contrary, these relationships involve university and pharma scientists working together.

See the article here.